Onconetix (NASDAQ:ONCO) Major Shareholder Sells $34,299.90 in Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt sold 49,710 shares of the company’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $0.69, for a total transaction of $34,299.90. Following the completion of the sale, the insider directly owned 33,649 shares of the company’s stock, valued at approximately $23,217.81. This represents a 59.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The stock was sold at an average price of $0.73, for a total transaction of $39,322.91.
• On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The stock was sold at an average price of $0.75, for a total transaction of $70,846.50.
• On Friday, April 17th, Financial Lp Hrt purchased 34,636 shares of Onconetix stock. The stock was bought at an average cost of $0.73 per share, with a total value of $25,284.28.
• On Wednesday, April 15th, Financial Lp Hrt purchased 92,554 shares of Onconetix stock. The stock was bought at an average cost of $0.76 per share, with a total value of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt purchased 74,350 shares of Onconetix stock. The stock was bought at an average cost of $0.77 per share, with a total value of $57,249.50.

Onconetix Trading Up 7.5%

ONCO stock traded up $0.05 on Wednesday, hitting $0.73. 1,588,917 shares of the company’s stock traded hands, compared to its average volume of 4,726,927. Onconetix, Inc. has a 1-year low of $0.66 and a 1-year high of $74.29. The stock has a market cap of $480,282.00, a price-to-earnings ratio of 0.00 and a beta of 3.63. The stock has a fifty day moving average of $2.62 and a 200-day moving average of $8.51.

Institutional Trading of Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix at the end of the most recent reporting period. Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.